T cell immunotherapy for cardiac fibrosis: mRNA starts the CAR

Ronald J Vagnozzi; Timothy A McKinsey

doi:10.1016/j.stem.2022.02.002

T cell immunotherapy for cardiac fibrosis: mRNA starts the CAR

Cell Stem Cell. 2022 Mar 3;29(3):352-354. doi: 10.1016/j.stem.2022.02.002.

Authors

Ronald J Vagnozzi¹, Timothy A McKinsey²

Affiliations

¹ Division of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; Consortium for Fibrosis Research & Translation, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; Gates Center for Regenerative Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA. Electronic address: [email protected].
² Division of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA; Consortium for Fibrosis Research & Translation, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA. Electronic address: [email protected].

PMID: 35245466
DOI: 10.1016/j.stem.2022.02.002

Abstract

Fibrosis, or chronic fibroblast activation and extracellular matrix deposition, underlies most cardiovascular diseases and remains challenging to target therapeutically. Reported in Science by Rurik et al., modified mRNA technology can reprogram endogenous T cells into fibroblast-ablating CAR-Ts in mouse hearts, offering a promising and tractable immunotherapy approach for tackling fibrosis.

Publication types

Comment

MeSH terms

Animals
Fibroblasts / pathology
Fibrosis
Immunotherapy*
Mice
RNA, Messenger / genetics
T-Lymphocytes*

Substances

RNA, Messenger